Global and United States Immuno-Oncology Market Report & Forecast 2022-2028

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.

Market Analysis and Insights: Global and United States Immuno-Oncology Market
This report focuses on global and United States Immuno-Oncology market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Immuno-Oncology market size is estimated to be worth US$ 50710 million in 2022 and is forecast to a readjusted size of US$ 116680 million by 2028 with a CAGR of 14.9% during the review period. Fully considering the economic change by this health crisis, by Type, Immune Checkpoint Inhibitors accounting for % of the Immuno-Oncology global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Hospitals was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

The industry's leading producers are Bristol-Myers Squibb, Merck & Co and Roche AG, with revenues of 27.89%, 22.10% and 20.85%, respectively, in 2019.

Global Immuno-Oncology Scope and Market Size
Immuno-Oncology market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Immuno-Oncology market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Immuno-Oncology market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type, the Immuno-Oncology market is segmented into
    Immune Checkpoint Inhibitors
    Cytokine-Based Immunotherapy
    Cancer Vaccines
    CAR-T Cell Therapy
    Others

Segment by Application, the Immuno-Oncology market is segmented into
    Hospitals
    Drugstores
    Others

Regional and Country-level Analysis
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        Taiwan
        Indonesia
        Thailand
        Malaysia
        Philippines
        Vietnam
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

Competitive Landscape and Immuno-Oncology Market Share Analysis
Immuno-Oncology market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Immuno-Oncology business, the date to enter into the Immuno-Oncology market, Revenue in Immuno-Oncology Business (2017-2022) & (US$ Million) introduction, recent developments, etc.

The major vendors covered:
    Bristol-Myers Squibb
    Merck & Co., Inc.
    Roche AG
    AstraZeneca, Plc
    Sanofi S.A.
    Dendreon Pharmaceuticals
    Novartis
    Gilead Sciences Inc.
    Merck KGaA

 1 Study Coverage
    1.1 Immuno-Oncology Revenue in Immuno-Oncology Business (2017-2022) & (US$ Million) Introduction
    1.2 Global Immuno-Oncology Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Immuno-Oncology Market Size for the Year 2017-2028
        1.2.2 Global Immuno-Oncology Market Size for the Year 2017-2028
    1.3 Immuno-Oncology Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.3.1 The Market Share of United States Immuno-Oncology in Global, 2017 VS 2022 VS 2028
        1.3.2 The Growth Rate of Immuno-Oncology Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.4 Immuno-Oncology Market Dynamics
        1.4.1 Immuno-Oncology Industry Trends
        1.4.2 Immuno-Oncology Market Drivers
        1.4.3 Immuno-Oncology Market Challenges
        1.4.4 Immuno-Oncology Market Restraints
    1.5 Study Objectives
    1.6 Years Considered

 2 Immuno-Oncology by Type
    2.1 Immuno-Oncology Market Segment by Type
        2.1.1 Immune Checkpoint Inhibitors
        2.1.2 Cytokine-Based Immunotherapy
        2.1.3 Cancer Vaccines
        2.1.4 CAR-T Cell Therapy
        2.1.5 Others
    2.2 Global Immuno-Oncology Market Size by Type (2017, 2022 & 2028)
    2.3 Global Immuno-Oncology Market Size by Type (2017-2028)
    2.4 United States Immuno-Oncology Market Size by Type (2017, 2022 & 2028)
    2.5 United States Immuno-Oncology Market Size by Type (2017-2028)

 3 Immuno-Oncology by Application
    3.1 Immuno-Oncology Market Segment by Application
        3.1.1 Hospitals
        3.1.2 Drugstores
        3.1.3 Others
    3.2 Global Immuno-Oncology Market Size by Application (2017, 2022 & 2028)
    3.3 Global Immuno-Oncology Market Size by Application (2017-2028)
    3.4 United States Immuno-Oncology Market Size by Application (2017, 2022 & 2028)
    3.5 United States Immuno-Oncology Market Size by Application (2017-2028)

 4 Global Immuno-Oncology Competitor Landscape by Company
    4.1 Global Immuno-Oncology Market Size by Company
        4.1.1 Top Global Immuno-Oncology Companies Ranked by Revenue (2021)
        4.1.2 Global Immuno-Oncology Revenue by Player (2017-2022)
    4.2 Global Immuno-Oncology Concentration Ratio (CR)
        4.2.1 Immuno-Oncology Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Companies of Immuno-Oncology in 2021
        4.2.3 Global Immuno-Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Immuno-Oncology Headquarters, Revenue in Immuno-Oncology Business (2017-2022) & (US$ Million) Type
        4.3.1 Global Immuno-Oncology Headquarters and Area Served
        4.3.2 Global Immuno-Oncology Companies Revenue in Immuno-Oncology Business (2017-2022) & (US$ Million) Type
        4.3.3 Date of International Companies Enter into Immuno-Oncology Market
    4.4 Companies Mergers & Acquisitions, Expansion Plans
    4.5 United States Immuno-Oncology Market Size by Company
        4.5.1 Top Immuno-Oncology Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Immuno-Oncology Revenue by Players (2020, 2021 & 2022)

 5 Global Immuno-Oncology Market Size by Region
    5.1 Global Immuno-Oncology Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Immuno-Oncology Market Size by Region (2017-2028)
        5.2.1 Global Immuno-Oncology Market Size by Region: 2017-2022
        5.2.2 Global Immuno-Oncology Market Size by Region (2023-2028)

 6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Immuno-Oncology Market Size YoY Growth 2017-2028
        6.1.2 North America Immuno-Oncology Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 U.S.
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Immuno-Oncology Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Immuno-Oncology Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
        6.2.12 Philippines
    6.3 Europe
        6.3.1 Europe Immuno-Oncology Market Size YoY Growth 2017-2028
        6.3.2 Europe Immuno-Oncology Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Immuno-Oncology Market Size YoY Growth 2017-2028
        6.4.2 Latin America Immuno-Oncology Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Immuno-Oncology Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Immuno-Oncology Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 UAE

 7 Company Profiles
    7.1 Bristol-Myers Squibb
        7.1.1 Bristol-Myers Squibb Company Details
        7.1.2 Bristol-Myers Squibb Business Overview
        7.1.3 Bristol-Myers Squibb Immuno-Oncology Introduction
        7.1.4 Bristol-Myers Squibb Revenue in Immuno-Oncology Business (2017-2022)
        7.1.5 Bristol-Myers Squibb Recent Development
    7.2 Merck & Co., Inc.
        7.2.1 Merck & Co., Inc. Company Details
        7.2.2 Merck & Co., Inc. Business Overview
        7.2.3 Merck & Co., Inc. Immuno-Oncology Introduction
        7.2.4 Merck & Co., Inc. Revenue in Immuno-Oncology Business (2017-2022)
        7.2.5 Merck & Co., Inc. Recent Development
    7.3 Roche AG
        7.3.1 Roche AG Company Details
        7.3.2 Roche AG Business Overview
        7.3.3 Roche AG Immuno-Oncology Introduction
        7.3.4 Roche AG Revenue in Immuno-Oncology Business (2017-2022)
        7.3.5 Roche AG Recent Development
    7.4 AstraZeneca, Plc
        7.4.1 AstraZeneca, Plc Company Details
        7.4.2 AstraZeneca, Plc Business Overview
        7.4.3 AstraZeneca, Plc Immuno-Oncology Introduction
        7.4.4 AstraZeneca, Plc Revenue in Immuno-Oncology Business (2017-2022)
        7.4.5 AstraZeneca, Plc Recent Development
    7.5 Sanofi S.A.
        7.5.1 Sanofi S.A. Company Details
        7.5.2 Sanofi S.A. Business Overview
        7.5.3 Sanofi S.A. Immuno-Oncology Introduction
        7.5.4 Sanofi S.A. Revenue in Immuno-Oncology Business (2017-2022)
        7.5.5 Sanofi S.A. Recent Development
    7.6 Dendreon Pharmaceuticals
        7.6.1 Dendreon Pharmaceuticals Company Details
        7.6.2 Dendreon Pharmaceuticals Business Overview
        7.6.3 Dendreon Pharmaceuticals Immuno-Oncology Introduction
        7.6.4 Dendreon Pharmaceuticals Revenue in Immuno-Oncology Business (2017-2022)
        7.6.5 Dendreon Pharmaceuticals Recent Development
    7.7 Novartis
        7.7.1 Novartis Company Details
        7.7.2 Novartis Business Overview
        7.7.3 Novartis Immuno-Oncology Introduction
        7.7.4 Novartis Revenue in Immuno-Oncology Business (2017-2022)
        7.7.5 Novartis Recent Development
    7.8 Gilead Sciences Inc.
        7.8.1 Gilead Sciences Inc. Company Details
        7.8.2 Gilead Sciences Inc. Business Overview
        7.8.3 Gilead Sciences Inc. Immuno-Oncology Introduction
        7.8.4 Gilead Sciences Inc. Revenue in Immuno-Oncology Business (2017-2022)
        7.8.5 Gilead Sciences Inc. Recent Development
    7.9 Merck KGaA
        7.9.1 Merck KGaA Company Details
        7.9.2 Merck KGaA Business Overview
        7.9.3 Merck KGaA Immuno-Oncology Introduction
        7.9.4 Merck KGaA Revenue in Immuno-Oncology Business (2017-2022)
        7.9.5 Merck KGaA Recent Development

 8 Research Findings and Conclusion

 9 Appendix
    9.1 Research Methodology
        9.1.1 Methodology/Research Approach
        9.1.2 Data Source
    9.2 Author Details
    9.3 Disclaimer

List of Tables
    Table 1. Immuno-Oncology Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Immuno-Oncology Market Trends
    Table 3. Immuno-Oncology Market Drivers
    Table 4. Immuno-Oncology Market Challenges
    Table 5. Immuno-Oncology Market Restraints
    Table 6. Global Immuno-Oncology Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Immuno-Oncology Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Immuno-Oncology Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Immuno-Oncology Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Immuno-Oncology Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Immuno-Oncology Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Immuno-Oncology Revenue Share by Player, 2017-2022
    Table 13. Global Immuno-Oncology Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Immuno-Oncology by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-Oncology as of 2021)
    Table 15. Top Players of Immuno-Oncology in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Immuno-Oncology Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Immuno-Oncology Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Immuno-Oncology Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Immuno-Oncology Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Immuno-Oncology Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Immuno-Oncology Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Immuno-Oncology Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Immuno-Oncology Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Immuno-Oncology Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Immuno-Oncology Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Immuno-Oncology Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Immuno-Oncology Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Immuno-Oncology Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Bristol-Myers Squibb Company Details
    Table 31. Bristol-Myers Squibb Business Overview
    Table 32. Bristol-Myers Squibb Immuno-Oncology Product
    Table 33. Bristol-Myers Squibb Revenue in Immuno-Oncology Business (2017-2022) & (US$ Million)
    Table 34. Bristol-Myers Squibb Recent Development
    Table 35. Merck & Co., Inc. Company Details
    Table 36. Merck & Co., Inc. Business Overview
    Table 37. Merck & Co., Inc. Immuno-Oncology Product
    Table 38. Merck & Co., Inc. Revenue in Immuno-Oncology Business (2017-2022) & (US$ Million)
    Table 39. Merck & Co., Inc. Recent Development
    Table 40. Roche AG Company Details
    Table 41. Roche AG Business Overview
    Table 42. Roche AG Immuno-Oncology Product
    Table 43. Roche AG Revenue in Immuno-Oncology Business (2017-2022) & (US$ Million)
    Table 44. Roche AG Recent Development
    Table 45. AstraZeneca, Plc Company Details
    Table 46. AstraZeneca, Plc Business Overview
    Table 47. AstraZeneca, Plc Immuno-Oncology Product
    Table 48. AstraZeneca, Plc Revenue in Immuno-Oncology Business (2017-2022) & (US$ Million)
    Table 49. AstraZeneca, Plc Recent Development
    Table 50. Sanofi S.A. Company Details
    Table 51. Sanofi S.A. Business Overview
    Table 52. Sanofi S.A. Immuno-Oncology Product
    Table 53. Sanofi S.A. Revenue in Immuno-Oncology Business (2017-2022) & (US$ Million)
    Table 54. Sanofi S.A. Recent Development
    Table 55. Dendreon Pharmaceuticals Company Details
    Table 56. Dendreon Pharmaceuticals Business Overview
    Table 57. Dendreon Pharmaceuticals Immuno-Oncology Product
    Table 58. Dendreon Pharmaceuticals Revenue in Immuno-Oncology Business (2017-2022) & (US$ Million)
    Table 59. Dendreon Pharmaceuticals Recent Development
    Table 60. Novartis Company Details
    Table 61. Novartis Business Overview
    Table 62. Novartis Immuno-Oncology Product
    Table 63. Novartis Revenue in Immuno-Oncology Business (2017-2022) & (US$ Million)
    Table 64. Novartis Recent Development
    Table 65. Gilead Sciences Inc. Company Details
    Table 66. Gilead Sciences Inc. Business Overview
    Table 67. Gilead Sciences Inc. Immuno-Oncology Product
    Table 68. Gilead Sciences Inc. Revenue in Immuno-Oncology Business (2017-2022) & (US$ Million)
    Table 69. Gilead Sciences Inc. Recent Development
    Table 70. Merck KGaA Company Details
    Table 71. Merck KGaA Business Overview
    Table 72. Merck KGaA Immuno-Oncology Product
    Table 73. Merck KGaA Revenue in Immuno-Oncology Business (2017-2022) & (US$ Million)
    Table 74. Merck KGaA Recent Development
    Table 75. Research Programs/Design for This Report
    Table 76. Key Data Information from Secondary Sources
    Table 77. Key Data Information from Primary Sources
List of Figures
    Figure 1. Immuno-Oncology Product Picture
    Figure 2. Global Immuno-Oncology Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Immuno-Oncology Market Size 2017-2028 (US$ Million)
    Figure 4. United States Immuno-Oncology Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Immuno-Oncology Market Size 2017-2028 (US$ Million)
    Figure 6. United States Immuno-Oncology Market Share in Global 2017-2028
    Figure 7. Immuno-Oncology Report Years Considered
    Figure 8. Product Picture of Immune Checkpoint Inhibitors
    Figure 9. Product Picture of Cytokine-Based Immunotherapy
    Figure 10. Product Picture of Cancer Vaccines
    Figure 11. Product Picture of CAR-T Cell Therapy
    Figure 12. Product Picture of Others
    Figure 13. Global Immuno-Oncology Market Share by Type in 2022 & 2028
    Figure 14. Global Immuno-Oncology Market Size by Type (2017-2028) & (US$ Million)
    Figure 15. Global Immuno-Oncology Market Share by Type (2017-2028)
    Figure 16. United States Immuno-Oncology Market Share by Type in 2022 & 2028
    Figure 17. United States Immuno-Oncology Market Size by Type (2017-2028) & (US$ Million)
    Figure 18. United States Immuno-Oncology Market Share by Type (2017-2028)
    Figure 19. Product Picture of Hospitals
    Figure 20. Product Picture of Drugstores
    Figure 21. Product Picture of Others
    Figure 22. Global Immuno-Oncology Market Share by Application in 2022 & 2028
    Figure 23. Global Immuno-Oncology Market Size by Application (2017-2028) & (US$ Million)
    Figure 24. Global Immuno-Oncology Market Share by Application (2017-2028)
    Figure 25. United States Immuno-Oncology Market Share by Application in 2022 & 2028
    Figure 26. United States Immuno-Oncology Market Size by Application (2017-2028) & (US$ Million)
    Figure 27. United States Immuno-Oncology Market Share by Application (2017-2028)
    Figure 28. North America Immuno-Oncology Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 29. U.S. Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 30. Canada Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 31. Europe Immuno-Oncology Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 32. Germany Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. France Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. U.K. Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Italy Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. Russia Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. Asia-Pacific Immuno-Oncology Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 38. China Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. Japan Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. South Korea Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. India Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Australia Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Taiwan Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Indonesia Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Thailand Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Malaysia Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Philippines Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Latin America Immuno-Oncology Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 49. Mexico Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Brazil Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Argentina Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Middle East & Africa Immuno-Oncology Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 53. Turkey Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Saudi Arabia Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 55. UAE Immuno-Oncology Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Bristol-Myers Squibb Revenue Growth Rate in Immuno-Oncology Business (2017-2022)
    Figure 57. Merck & Co., Inc. Revenue Growth Rate in Immuno-Oncology Business (2017-2022)
    Figure 58. Roche AG Revenue Growth Rate in Immuno-Oncology Business (2017-2022)
    Figure 59. AstraZeneca, Plc Revenue Growth Rate in Immuno-Oncology Business (2017-2022)
    Figure 60. Sanofi S.A. Revenue Growth Rate in Immuno-Oncology Business (2017-2022)
    Figure 61. Dendreon Pharmaceuticals Revenue Growth Rate in Immuno-Oncology Business (2017-2022)
    Figure 62. Novartis Revenue Growth Rate in Immuno-Oncology Business (2017-2022)
    Figure 63. Gilead Sciences Inc. Revenue Growth Rate in Immuno-Oncology Business (2017-2022)
    Figure 64. Merck KGaA Revenue Growth Rate in Immuno-Oncology Business (2017-2022)
    Figure 65. Bottom-up and Top-down Approaches for This Report
    Figure 66. Data Triangulation
    Figure 67. Key Executives Interviewed

Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.

Market Analysis and Insights: Global and United States Immuno-Oncology Market
This report focuses on global and United States Immuno-Oncology market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Immuno-Oncology market size is estimated to be worth US$ 50710 million in 2022 and is forecast to a readjusted size of US$ 116680 million by 2028 with a CAGR of 14.9% during the review period. Fully considering the economic change by this health crisis, by Type, Immune Checkpoint Inhibitors accounting for % of the Immuno-Oncology global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Hospitals was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

The industry's leading producers are Bristol-Myers Squibb, Merck & Co and Roche AG, with revenues of 27.89%, 22.10% and 20.85%, respectively, in 2019.

Global Immuno-Oncology Scope and Market Size
Immuno-Oncology market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Immuno-Oncology market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Immuno-Oncology market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type, the Immuno-Oncology market is segmented into
    Immune Checkpoint Inhibitors
    Cytokine-Based Immunotherapy
    Cancer Vaccines
    CAR-T Cell Therapy
    Others

Segment by Application, the Immuno-Oncology market is segmented into
    Hospitals
    Drugstores
    Others

Regional and Country-level Analysis
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        Taiwan
        Indonesia
        Thailand
        Malaysia
        Philippines
        Vietnam
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

Competitive Landscape and Immuno-Oncology Market Share Analysis
Immuno-Oncology market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Immuno-Oncology business, the date to enter into the Immuno-Oncology market, Revenue in Immuno-Oncology Business (2017-2022) & (US$ Million) introduction, recent developments, etc.

The major vendors covered:
    Bristol-Myers Squibb
    Merck & Co., Inc.
    Roche AG
    AstraZeneca, Plc
    Sanofi S.A.
    Dendreon Pharmaceuticals
    Novartis
    Gilead Sciences Inc.
    Merck KGaA